Navigation Links
Intensive statin therapy may partially reverse plaque build-up in arteries

A study presented today at the American College of Cardiology's 55th Annual Scientific Session demonstrates, for the first time, that very intensive cholesterol lowering with a statin drug can regress (partially reverse) the buildup of plaque in the coronary arteries.

This finding has never before been observed in a study using statin drugs, the most commonly used cholesterol lowering treatment. Previous research had indicated that intensive statin therapy could prevent the progression of coronary atherosclerosis, or arterial plaque build-up, but not actually reduce disease burden. ACC.06 is the premier cardiovascular medical meeting, bringing together more than 30,000 cardiologists to further breakthroughs in cardiovascular medicine.

The intense statin therapy used in this study resulted in significant regression of atherosclerosis as measured by intravascular ultrasound (IVUS), a technique in which a tiny ultrasound probe is inserted into the coronary arteries to measure plaque. The study showed that regression occurred for all three pre-specified IVUS measures of disease burden. The mean baseline LDL cholesterol of 130.4 mg/dL dropped to 60.8 mg/dL in the study patients, an reduction of 53.2 percent. This is the largest reduction in cholesterol ever observed in a major statin outcome trial. Mean HDL cholesterol (43.1 mg/dL at baseline) increased to 49.0 mg/dL, a 14.7 percent increase, which was also unprecedented. The arterial plaque overall was reduced by 6.8 to 9.1% for the various measures of disease burden.

This study was known by the acronym of ASTEROID (A Study To Evaluate the Effect of Rosuvastatin On Intravascular Ultrasound-Derived Coronary Atheroma Burden [ASTEROID] Trial). The trial was conducted at 53 community and tertiary care centers in the United States, Canada, Europe, and Australia. A total of 507 patients had baseline intravascular ultrasound (IVUS) examination and received 40 mg daily of rosuvastatin (brand name Cr
'"/>

Source:American College of Cardiology


Page: 1 2

Related biology news :

1. President Bushs cut to AIDS prevention in Africa would be devastating
2. Novel targets found for the development of drugs to complement, or replace, statins
3. Quick identification needed to save Floridas citrus industry from devastating disease
4. Patients can report statins adverse effects on new web site
5. Adding Radiation Therapy To Chemotherapy Improves Survival In Patients With High-risk Breast Cancer
6. Columbia research lifts major hurdle to gene therapy for cancer
7. Combination therapy boosts effectiveness of telomere-directed cancer cell death
8. Gene therapy converts dead bone graft to new, living tissue
9. Study identifies predictors of HIV drug resistance in patients beginning triple therapy
10. New imaging method gives early indication if brain cancer therapy is effective, U-M study shows
11. Muscle-targeted gene therapy reverses rare muscular dystrophy in mice
Post Your Comments:
(Date:2/25/2015)... Feb. 25, 2015  ABC Financial Services (ABC), ... the Health and Fitness Industry, today announced enhancements ... MYiCLUBonline.  The latest upgrade includes advances to the ... cardless check-in via Identity One fingerprint biometrics. The ... through interactive displays at the International Health, Racquet ...
(Date:2/24/2015)... , Feb. 24, 2015 Research and ... the addition of the "Global 2D Gesture ... The analysts forecast the Global ... CAGR of 32.12% over the period 2014-2019 ... in non-traditional sectors is one of the major ...
(Date:2/18/2015)... 18, 2015  Cepheid (NASDAQ: CPHD ) today ... conferences, and invited investors to participate via webcast. , ... Tuesday, March 3, 2015 at 11.20 a.m. Eastern ... Orlando, FL Wednesday, March 4, 2015 at 10.25 ... the live webcasts for these events, please visit Cepheid,s website ...
Breaking Biology News(10 mins):ABC Financial Unveils New Software Enhancements 2ABC Financial Unveils New Software Enhancements 3Global 2D Gesture Recognition Market 2015-2019 with Cognitec Systems, CogniVue, eyeSight Mobile Technologies & PointGrab Dominating 2Cepheid to Webcast Upcoming Financial Presentations 2
... with salty, undrinkable water for fish production is ... be an effective potential alternative livelihood for people ... drylands. In a report released today, researchers ... on Agricultural Research in Dryland Areas (ICARDA), and ...
... CLEVELAND November 10, 2008 A multidisciplinary research team ... Ph.D., a professor in the School of Medicine,s Department ... a number of birth defects that affect the development ... jaw, palate, brain and heart are relatively common congenital ...
... of invasive marine is one of many research results ... the First World Conference on Marine Biodiversity, Ciudad de ... report that invasive species of marine macroalgae spread at ... that covered by invasive terrestrial plants. The difference ...
Cached Biology News:'Arid aquaculture' among livelihoods promoted to relieve worsening pressure on world's drylands 2'Arid aquaculture' among livelihoods promoted to relieve worsening pressure on world's drylands 3'Arid aquaculture' among livelihoods promoted to relieve worsening pressure on world's drylands 4'Arid aquaculture' among livelihoods promoted to relieve worsening pressure on world's drylands 5Case Western Reserve University uncovers genetic basis for some birth defects 2Marine invasive species advance 50km per decade, World Conference on Marine Biodiversity told 2Marine invasive species advance 50km per decade, World Conference on Marine Biodiversity told 3Marine invasive species advance 50km per decade, World Conference on Marine Biodiversity told 4
(Date:3/4/2015)... 2015  BioClinica®, Inc., a leading specialty ... announced that clinical trial professionals representing 20 ... annual European User Conference in ... use of its eClinical technologies to overcome ... the Microsoft Office-Smart OnPoint CTMS; Express EDC; ...
(Date:3/4/2015)... , March 4, 2015 ... Paris in December 2011, ... of yttrium-90 resin microspheres versus sorafenib in advanced hepatocellular ... expected late 2016.   SARAH, a large ... cancer (hepatocellular carcinoma, or HCC) has completed patient enrolment, ...
(Date:3/3/2015)... 3, 2015 /PRNewswire/ - Aptose Biosciences Inc. (NASDAQ: APTO, ... molecular diagnostics that target the underlying mechanisms of cancer, ... period ended December 31, 2014. Effective July ... from May 31 to December 31. As a result ... are for the quarter and the seven months ended ...
(Date:3/3/2015)... 03, 2015 Experts and industry insiders ... one event: the Alltech REBELation exploring innovation, inspiration and ... Now in its 31st year, Alltech’s annual international conference ... and the opportunity to join the REBELation at an ... 11:59 p.m. EST, at which point the standard early ...
Breaking Biology Technology:BioClinica Teams With Pharma To Tackle Clinical Trial Challenges In Europe 2BioClinica Teams With Pharma To Tackle Clinical Trial Challenges In Europe 3Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 2Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 3Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 4Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 5Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 2Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 3Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 4Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 5Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 6Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 7Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 8Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 9Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 10Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 11Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 12World-renowned Leaders, Authors and Businesspeople Join the Alltech REBELation 2World-renowned Leaders, Authors and Businesspeople Join the Alltech REBELation 3World-renowned Leaders, Authors and Businesspeople Join the Alltech REBELation 4
... Md., Aug. 6 ImQuest BioSciences announced,today ... National Institutes of,Health to support the development ... topical microbicide product. ImQuest and a consortium ... will,develop a highly innovative product from the ...
... Pressure,BioSciences, Inc. (Nasdaq: PBIO ) ("PBI" ... its pressure cycling technology ("PCT")-enhanced,trypsin digestion application for ... of products. Named "Proteolysis (Trypsin)-PrEP", this new,PCT-enhanced processing ... Development of Innovative Therapeutics Expo 2008, being held,this ...
... Integrated Nanochannel Chip and Reader for,Single-Molecule Mapping, Enabling Direct ... Strands of DNA in Context and ... BioNanomatrix, Inc., a developer,of breakthrough nanoscale whole genome ... today announced,receipt of a grant from the National Human ...
Cached Biology Technology:ImQuest Receives $6.4 M Five Year Award from NIH to Develop Long-Lasting Combination Topical Microbicides To Prevent HIV Transmission 2ImQuest Receives $6.4 M Five Year Award from NIH to Develop Long-Lasting Combination Topical Microbicides To Prevent HIV Transmission 3Pressure BioSciences, Inc. Announces the Market Release of its PCT-Enhanced Trypsin Digestion Application for Proteomics 2Pressure BioSciences, Inc. Announces the Market Release of its PCT-Enhanced Trypsin Digestion Application for Proteomics 3Pressure BioSciences, Inc. Announces the Market Release of its PCT-Enhanced Trypsin Digestion Application for Proteomics 4Pressure BioSciences, Inc. Announces the Market Release of its PCT-Enhanced Trypsin Digestion Application for Proteomics 5BioNanomatrix Awarded New NIH Grant for Development of Nanoscale Platform for Single-Molecule DNA Mapping and Haplotype Applications 2BioNanomatrix Awarded New NIH Grant for Development of Nanoscale Platform for Single-Molecule DNA Mapping and Haplotype Applications 3
Coverslips for Microarrays, 1. *Category: MICROARRAY ACCESSORIES....
... ScriptCap™ 2'-O-Methyltransferase converts Cap 0 (or Cap ... Cap 1 structure has been shown to ... to 50%. This improvement is seen in ... m7G Capping System as well as those ...
Form: Ready to use Applications: ELISA...
Form: Ready to use Applications: ELISA...
Biology Products: